Pharma on $55B shopping spree

Posted 14 May 2024 PM

M&A activity is off to a strong start for 2024 with a total of AU$55 billion (US$36.46 billion) in upfront spending recorded for Q1, marking the fifth highest quarterly total since the beginning of 2020.

A new Evaluate report shows seven biopharma acquisitions valued at more than US$1 billion up front were recorded during Q1, including one above the US$10 billion mark.

To see the whole article, please login